Skip to main content
Top
Published in: Clinical & Experimental Metastasis 6/2012

01-08-2012 | Research Paper

CCL27–CCR10 and CXCL12–CXCR4 chemokine ligand-receptor mRNA expression ratio: new predictive factors of tumor progression in cutaneous malignant melanoma

Authors: Carlos Monteagudo, David Ramos, Ana Pellín-Carcelén, Rosario Gil, Robert C. Callaghan, José M. Martín, Vicent Alonso, Amelia Murgui, Lara Navarro, Silvia Calabuig, José Antonio López-Guerrero, Esperanza Jordá, Antonio Pellín

Published in: Clinical & Experimental Metastasis | Issue 6/2012

Login to get access

Abstract

CXCR4, CCR7 and CCR10 chemokine receptors are known to be involved in melanoma metastasis. Our goal was to compare the relative intratumoral mRNA expression of these receptors with that of their corresponding chemokine ligands, CXCL12, CCL19, CCL21, and CCL27 across the full spectrum of human melanoma progression: thin and thick primary melanomas, as well as “in transit”, lymph node, and distant metastases. Expression was quantified by real-time RT-PCR in 103 melanoma samples: 51 primary tumors and 52 metastases. Particular emphasis was focused on chemokine ligand-receptor expression ratios. Immunohistochemistry was performed to identify the cell types expressing these molecules. CXCL12–CXCR4 and CCL27–CCR10 ratios were higher in thin than in thick primary melanomas, and all four chemokine-receptor ratios were higher in primary tumors than in melanoma metastases. CCL27–CCR10 and CXCL12–CXCR4 expression ratios in primary tumors were inversely associated with the development of distant metastases, and improved the predictive value of tumor thickness for distant metastasis, which is important since chemokine ligand-receptor ratios are not affected by the endogenous gene employed for normalizing mRNA expression. Both receptor and ligand immunolabeling were detected in neoplastic cells suggesting autocrine mechanisms. Our results support the concept that low CCL27/CCR10 and CXCL12/CXCR4 intratumoral mRNA ratios are associated with melanoma progression, and in combination with Breslow thickness, are the best predictive factors for the development of distant metastases in primary cutaneous melanoma.
Literature
1.
go back to reference Kuphal S, Bosserhoff A (2009) Recent progress in understanding the pathology of malignant melanoma. J Pathol 219:400–409PubMedCrossRef Kuphal S, Bosserhoff A (2009) Recent progress in understanding the pathology of malignant melanoma. J Pathol 219:400–409PubMedCrossRef
2.
3.
go back to reference Thompson JF, Scolier RA, Kefford RF (2005) Cutaneous melanoma. Lancet 365:687–701PubMed Thompson JF, Scolier RA, Kefford RF (2005) Cutaneous melanoma. Lancet 365:687–701PubMed
4.
go back to reference Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA (2009) Increasing burden of melanoma in the United States. J Invest Dermatol 129:1666–1674PubMedCrossRef Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA (2009) Increasing burden of melanoma in the United States. J Invest Dermatol 129:1666–1674PubMedCrossRef
5.
go back to reference Burton RC, Armstrong BK (1994) Recent incidence trends imply a nonmetastasizing form of invasive melanoma. Melanoma Res 4:107–113PubMedCrossRef Burton RC, Armstrong BK (1994) Recent incidence trends imply a nonmetastasizing form of invasive melanoma. Melanoma Res 4:107–113PubMedCrossRef
6.
go back to reference Lambert L (2002) Epidemic of malignant melanoma. True increase or better detection? JAMA 287:2201CrossRef Lambert L (2002) Epidemic of malignant melanoma. True increase or better detection? JAMA 287:2201CrossRef
7.
go back to reference Gimotty PA, Guerri D, Ming ME et al (2004) The primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol 22:3668–3676PubMedCrossRef Gimotty PA, Guerri D, Ming ME et al (2004) The primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol 22:3668–3676PubMedCrossRef
8.
go back to reference Balch CM, Gershenwald JE, Soong SJ et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199–6206PubMedCrossRef Balch CM, Gershenwald JE, Soong SJ et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199–6206PubMedCrossRef
9.
go back to reference Kalady MF, White RR, Johnson JL, Tyler DS, Seigler HF (2003) Thin melanomas: predictive lethal characteristics from a 30-year clinical experience. Ann Surg 238:528–535PubMed Kalady MF, White RR, Johnson JL, Tyler DS, Seigler HF (2003) Thin melanomas: predictive lethal characteristics from a 30-year clinical experience. Ann Surg 238:528–535PubMed
10.
go back to reference King R, Googe PB, Mihm MC Jr (2000) Thin melanomas. Clin Lab Med 20:713–729PubMed King R, Googe PB, Mihm MC Jr (2000) Thin melanomas. Clin Lab Med 20:713–729PubMed
11.
go back to reference Müller A, Homey B, Soto H et al (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50–56PubMedCrossRef Müller A, Homey B, Soto H et al (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50–56PubMedCrossRef
14.
go back to reference Kulbe H, Levinson NR, Balkwill F, Wilson JL (2004) The chemokine network in cancer–much more than directing cell movement. Int J Dev Biol 48:489–496PubMedCrossRef Kulbe H, Levinson NR, Balkwill F, Wilson JL (2004) The chemokine network in cancer–much more than directing cell movement. Int J Dev Biol 48:489–496PubMedCrossRef
15.
go back to reference Lazennec G, Richmond A (2010) Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med 16:133–144PubMedCrossRef Lazennec G, Richmond A (2010) Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med 16:133–144PubMedCrossRef
16.
17.
go back to reference Sun YX, Wang J, Shelburne CE et al (2003) Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 89:462–473PubMedCrossRef Sun YX, Wang J, Shelburne CE et al (2003) Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 89:462–473PubMedCrossRef
18.
go back to reference Salmaggi A, Maderna E, Calatozzolo C et al (2009) CXCL12, CXCR4 and CXCR7 expression in brain metastases. Cancer Biol Ther 8:1608–1614PubMedCrossRef Salmaggi A, Maderna E, Calatozzolo C et al (2009) CXCL12, CXCR4 and CXCR7 expression in brain metastases. Cancer Biol Ther 8:1608–1614PubMedCrossRef
19.
go back to reference Liang Z, Wu T, Lou H et al (2004) Inhibition of breast cancer metastasis by selective polypeptide against CXCR4. Cancer Res 64:4302–4308PubMedCrossRef Liang Z, Wu T, Lou H et al (2004) Inhibition of breast cancer metastasis by selective polypeptide against CXCR4. Cancer Res 64:4302–4308PubMedCrossRef
20.
go back to reference Takenaga M, Tamamura H, Hiramatsu K et al (2004) A single treatment with microcapsules containing a CXCR4 antagonist suppresses pulmonary metastasis of murine melanoma. Biochem Biophys Res Commun 320:226–232PubMedCrossRef Takenaga M, Tamamura H, Hiramatsu K et al (2004) A single treatment with microcapsules containing a CXCR4 antagonist suppresses pulmonary metastasis of murine melanoma. Biochem Biophys Res Commun 320:226–232PubMedCrossRef
21.
go back to reference Kim SY, Lee CH, Midura BV et al (2008) Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis 25:201–211PubMedCrossRef Kim SY, Lee CH, Midura BV et al (2008) Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis 25:201–211PubMedCrossRef
22.
go back to reference Bartolomé RA, Ferreiro S, Miquilena-Colina ME et al (2009) The chemokine receptor CXCR4 and the metalloproteinase MT1-MMP are mutually required during melanoma metastasis to lungs. Am J Pathol 174:602–612PubMedCrossRef Bartolomé RA, Ferreiro S, Miquilena-Colina ME et al (2009) The chemokine receptor CXCR4 and the metalloproteinase MT1-MMP are mutually required during melanoma metastasis to lungs. Am J Pathol 174:602–612PubMedCrossRef
23.
go back to reference Robledo MM, Bartolomé RA, Longo N et al (2001) Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells. J Biol Chem 276:45098–45105PubMedCrossRef Robledo MM, Bartolomé RA, Longo N et al (2001) Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells. J Biol Chem 276:45098–45105PubMedCrossRef
24.
go back to reference Scala S, Ottaiano A, Ascierto PA et al (2005) Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 11:1835–1841PubMedCrossRef Scala S, Ottaiano A, Ascierto PA et al (2005) Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 11:1835–1841PubMedCrossRef
25.
go back to reference Scala S, Giuliano P, Ascierto PA et al (2006) Human melanoma metastases express functional CXCR4. Clin Cancer Res 12:2427–2433PubMedCrossRef Scala S, Giuliano P, Ascierto PA et al (2006) Human melanoma metastases express functional CXCR4. Clin Cancer Res 12:2427–2433PubMedCrossRef
26.
go back to reference Longo-Imedio MI, Longo N, Treviño I, Lázaro P, Sanchez-Mateos P (2005) Clinical significance of CXCR3 and CXCR4 expression in primary melanoma. Int J Cancer 117:861–865PubMedCrossRef Longo-Imedio MI, Longo N, Treviño I, Lázaro P, Sanchez-Mateos P (2005) Clinical significance of CXCR3 and CXCR4 expression in primary melanoma. Int J Cancer 117:861–865PubMedCrossRef
27.
go back to reference Schioppa T, Uranchimeg B, Saccani A et al (2003) Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 198:1391–1402PubMedCrossRef Schioppa T, Uranchimeg B, Saccani A et al (2003) Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 198:1391–1402PubMedCrossRef
28.
go back to reference Schutyser E, Su Y, Yu Y et al (2007) Hypoxia enhances CXCR4 expression in human microvascular endothelial cells and human melanoma cells. Eur Cytokine Netw 18:59–70PubMed Schutyser E, Su Y, Yu Y et al (2007) Hypoxia enhances CXCR4 expression in human microvascular endothelial cells and human melanoma cells. Eur Cytokine Netw 18:59–70PubMed
29.
go back to reference Brandt S, Dambacher J, Beigel F et al (2005) CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion and MMP-9 activation. Exp Cell Res 310:117–130CrossRef Brandt S, Dambacher J, Beigel F et al (2005) CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion and MMP-9 activation. Exp Cell Res 310:117–130CrossRef
30.
go back to reference Petit I, Szyper-Kravitz M, Nagler A et al (2002) G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 3:687–694PubMedCrossRef Petit I, Szyper-Kravitz M, Nagler A et al (2002) G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 3:687–694PubMedCrossRef
31.
go back to reference Hasegawa H, Nomura T, Kohno M et al (2000) Increased chemokine receptor CCR7/EBI1 expression enhances the infiltration of lymphoid organs by adult T cell leukemia cells. Blood 95:30–38PubMed Hasegawa H, Nomura T, Kohno M et al (2000) Increased chemokine receptor CCR7/EBI1 expression enhances the infiltration of lymphoid organs by adult T cell leukemia cells. Blood 95:30–38PubMed
32.
go back to reference Wiley HE, Gonzalez EB, Maki W, Wu MT, Hwang ST (2001) Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J Natl Cancer Inst 93:1638–1643PubMedCrossRef Wiley HE, Gonzalez EB, Maki W, Wu MT, Hwang ST (2001) Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J Natl Cancer Inst 93:1638–1643PubMedCrossRef
33.
go back to reference Forster R, Ohl L, Henning G (2001) Lessons learned from lymphocytes: CC chemokine receptor–7 involved in lymphogenic metastasis of melanoma. J Natl Cancer Inst 93:1588–1589PubMedCrossRef Forster R, Ohl L, Henning G (2001) Lessons learned from lymphocytes: CC chemokine receptor–7 involved in lymphogenic metastasis of melanoma. J Natl Cancer Inst 93:1588–1589PubMedCrossRef
34.
go back to reference Mashino K, Sadanaga N, Yamaguchi H et al (2002) Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res 62:2937–2941PubMed Mashino K, Sadanaga N, Yamaguchi H et al (2002) Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res 62:2937–2941PubMed
35.
go back to reference Takanami I (2003) Overexpression of CCR7 mRNA in nonsmall cell lung cancer: correlation with lymph node metastasis. Int J Cancer 105:186–189PubMedCrossRef Takanami I (2003) Overexpression of CCR7 mRNA in nonsmall cell lung cancer: correlation with lymph node metastasis. Int J Cancer 105:186–189PubMedCrossRef
36.
go back to reference Ding Y, Shimada Y, Maeda M et al (2003) Association of CC chemokine receptor 7 with lymph node metastasis of esophageal squamous cell carcinoma. Clin Cancer Res 9:3406–3407PubMed Ding Y, Shimada Y, Maeda M et al (2003) Association of CC chemokine receptor 7 with lymph node metastasis of esophageal squamous cell carcinoma. Clin Cancer Res 9:3406–3407PubMed
37.
go back to reference Carrière V, Colisson R, Jiguet-Jiglaire C et al (2005) Cancer cells regulate lymphocyte recruitment and leukocyte-endothelium interactions in the tumor-draining lymph node. Cancer Res 65:11639–11648PubMedCrossRef Carrière V, Colisson R, Jiguet-Jiglaire C et al (2005) Cancer cells regulate lymphocyte recruitment and leukocyte-endothelium interactions in the tumor-draining lymph node. Cancer Res 65:11639–11648PubMedCrossRef
38.
go back to reference Takeuchi H, Fujimoto A, Tanaka M, Yamano T, Hsueh E, Hoon DS (2004) CCL21 chemokine regulates receptor CCR7 bearing malignant melanoma cells. Clin Cancer Res 10:2351–2358PubMedCrossRef Takeuchi H, Fujimoto A, Tanaka M, Yamano T, Hsueh E, Hoon DS (2004) CCL21 chemokine regulates receptor CCR7 bearing malignant melanoma cells. Clin Cancer Res 10:2351–2358PubMedCrossRef
39.
go back to reference Shields JD, Fleury ME, Yong C, Tomei AA, Randolph GJ, Swartz MA (2007) Autologous chemotaxis as a mechanism of tumor cell homing to lymphatics via interstitial flow and autocrine CCR7 signaling. Cancer Cell 11:526–538PubMedCrossRef Shields JD, Fleury ME, Yong C, Tomei AA, Randolph GJ, Swartz MA (2007) Autologous chemotaxis as a mechanism of tumor cell homing to lymphatics via interstitial flow and autocrine CCR7 signaling. Cancer Cell 11:526–538PubMedCrossRef
40.
go back to reference Shields JD, Kourtis IC, Tomei AA, Roberts JM, Swartz MA (2010) Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science 328:749–752PubMedCrossRef Shields JD, Kourtis IC, Tomei AA, Roberts JM, Swartz MA (2010) Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science 328:749–752PubMedCrossRef
41.
go back to reference Simonetti O, Goteri G, Lucarini G et al (2006) Potential role of CCL27 and CCR10 expression in melanoma progression and immune escape. Eur J Cancer 42:1181–1187PubMedCrossRef Simonetti O, Goteri G, Lucarini G et al (2006) Potential role of CCL27 and CCR10 expression in melanoma progression and immune escape. Eur J Cancer 42:1181–1187PubMedCrossRef
42.
go back to reference Pivarcsi A, Müller A, Hippe A et al (2007) Tumor immune escape by the loss of homeostatic chemokine expression. Proc Natl Acad Sci USA 104:19055–19060PubMedCrossRef Pivarcsi A, Müller A, Hippe A et al (2007) Tumor immune escape by the loss of homeostatic chemokine expression. Proc Natl Acad Sci USA 104:19055–19060PubMedCrossRef
43.
go back to reference Jaeger J, Koczan D, Thiesen HJ et al (2007) Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin Cancer Res 13:806–815PubMedCrossRef Jaeger J, Koczan D, Thiesen HJ et al (2007) Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin Cancer Res 13:806–815PubMedCrossRef
44.
go back to reference Goidin D, Mamessier A, Staquet MJ, Schmitt D, Berthier-Vergnes O (2001) Ribosomal 18S RNA prevails over glyceraldehyde-3-phosphate dehydrogenase and β-actin genes as internal standard for quantitative comparison of mRNA levels in invasive and noninvasive human melanoma cell subpopulations. Anal Biochem 295:17–21PubMedCrossRef Goidin D, Mamessier A, Staquet MJ, Schmitt D, Berthier-Vergnes O (2001) Ribosomal 18S RNA prevails over glyceraldehyde-3-phosphate dehydrogenase and β-actin genes as internal standard for quantitative comparison of mRNA levels in invasive and noninvasive human melanoma cell subpopulations. Anal Biochem 295:17–21PubMedCrossRef
45.
go back to reference Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCt method. Methods 25:402–408PubMedCrossRef Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCt method. Methods 25:402–408PubMedCrossRef
47.
go back to reference Richmond A, Yang J, Su Y (2009) The good and the bad of chemokines/chemokine receptors in melanoma. Pigment Cell Melanoma Res 22:175–186PubMedCrossRef Richmond A, Yang J, Su Y (2009) The good and the bad of chemokines/chemokine receptors in melanoma. Pigment Cell Melanoma Res 22:175–186PubMedCrossRef
48.
go back to reference Thellin O, Zorzi W, Lakaye B et al (1999) Housekeeping genes as internal standards: use and limits. J Biotechnol 75:291–295PubMedCrossRef Thellin O, Zorzi W, Lakaye B et al (1999) Housekeeping genes as internal standards: use and limits. J Biotechnol 75:291–295PubMedCrossRef
49.
go back to reference Dheda K, Huggett JF, Bustin SA, Johnson MA, Rook G, Zumla A (2004) Validation of housekeeping genes for normalizing RNA expression in real-time PCR. Biotechniques 37:112–119PubMed Dheda K, Huggett JF, Bustin SA, Johnson MA, Rook G, Zumla A (2004) Validation of housekeeping genes for normalizing RNA expression in real-time PCR. Biotechniques 37:112–119PubMed
50.
go back to reference Bustin SA, Nolan T (2004) Pitfalls of quantitative real-time reverse-transcription polymerase chain reaction. J Biomol Tech 15:155–166PubMed Bustin SA, Nolan T (2004) Pitfalls of quantitative real-time reverse-transcription polymerase chain reaction. J Biomol Tech 15:155–166PubMed
51.
go back to reference Gilsbach R, Kouta M, Bonisch H, Bruss M (2006) Comparison of in vitro and in vivo reference genes for internal standardization of real-time PCR data. Biotechniques 40:173–177PubMedCrossRef Gilsbach R, Kouta M, Bonisch H, Bruss M (2006) Comparison of in vitro and in vivo reference genes for internal standardization of real-time PCR data. Biotechniques 40:173–177PubMedCrossRef
52.
go back to reference Giricz O, Lauer-Fields JL, Fields GB (2008) The normalization of gene expression data in melanoma: investigating the use of glyceraldehyde 3-phosphate dehydrogenase and 18S ribosomal RNA as internal reference genes for quantitative real-time PCR. Anal Biochem 380:137–139PubMedCrossRef Giricz O, Lauer-Fields JL, Fields GB (2008) The normalization of gene expression data in melanoma: investigating the use of glyceraldehyde 3-phosphate dehydrogenase and 18S ribosomal RNA as internal reference genes for quantitative real-time PCR. Anal Biochem 380:137–139PubMedCrossRef
53.
go back to reference Minner F, Poumay Y (2009) Candidate housekeeping genes require evaluation before their selection for studies of human epidermal keratinocytes. J Invest Dermatol 129:770–773PubMedCrossRef Minner F, Poumay Y (2009) Candidate housekeeping genes require evaluation before their selection for studies of human epidermal keratinocytes. J Invest Dermatol 129:770–773PubMedCrossRef
54.
go back to reference Bär M, Bär D, Lehmann B (2009) Selection and validation of candidate housekeeping genes for studies of human keratinocytes—review and recommendations. J Invest Dermatol 129:535–537PubMedCrossRef Bär M, Bär D, Lehmann B (2009) Selection and validation of candidate housekeeping genes for studies of human keratinocytes—review and recommendations. J Invest Dermatol 129:535–537PubMedCrossRef
55.
go back to reference Peled A, Petit I, Kollet O et al (1999) Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 283:845–848PubMedCrossRef Peled A, Petit I, Kollet O et al (1999) Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 283:845–848PubMedCrossRef
56.
go back to reference Murakami T, Maki W, Cardones AR et al (2002) Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res 62:7328–7334PubMed Murakami T, Maki W, Cardones AR et al (2002) Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res 62:7328–7334PubMed
57.
go back to reference Guleng B, Tateishi K, Ohta M et al (2005) Blockade of the stromal cell-derived factor/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner. Cancer Res 65:5864–5871PubMedCrossRef Guleng B, Tateishi K, Ohta M et al (2005) Blockade of the stromal cell-derived factor/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner. Cancer Res 65:5864–5871PubMedCrossRef
58.
go back to reference Orimo A, Gupta PB, Sgroi DC et al (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121:335–348PubMedCrossRef Orimo A, Gupta PB, Sgroi DC et al (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121:335–348PubMedCrossRef
59.
go back to reference Bartolomé RA, Gálvez BG, Longo N, Baleux F, Van Muijen GN, Sánchez-Mateos P (2004) Stromal cell-derived factor-1α promotes melanoma cell invasion across basement membranes involving stimulation of membrane-type 1 matrix metalloproteinase and Rho GTPase activities. Cancer Res 64:2534–2543PubMedCrossRef Bartolomé RA, Gálvez BG, Longo N, Baleux F, Van Muijen GN, Sánchez-Mateos P (2004) Stromal cell-derived factor-1α promotes melanoma cell invasion across basement membranes involving stimulation of membrane-type 1 matrix metalloproteinase and Rho GTPase activities. Cancer Res 64:2534–2543PubMedCrossRef
60.
go back to reference Kochetkova M, Kumar S, McColl SR (2009) Chemokine receptors CXCR4 and CCR7 promote metastasis by preventing anoikis in cancer cells. Cell Death Differ 16:664–673PubMedCrossRef Kochetkova M, Kumar S, McColl SR (2009) Chemokine receptors CXCR4 and CCR7 promote metastasis by preventing anoikis in cancer cells. Cell Death Differ 16:664–673PubMedCrossRef
61.
go back to reference Murakami T, Cardones AR, Finkelstein SE et al (2003) Immune evasion by murine melanoma mediated through chemokine receptor-10. J Exp Med 198:1337–7334PubMedCrossRef Murakami T, Cardones AR, Finkelstein SE et al (2003) Immune evasion by murine melanoma mediated through chemokine receptor-10. J Exp Med 198:1337–7334PubMedCrossRef
Metadata
Title
CCL27–CCR10 and CXCL12–CXCR4 chemokine ligand-receptor mRNA expression ratio: new predictive factors of tumor progression in cutaneous malignant melanoma
Authors
Carlos Monteagudo
David Ramos
Ana Pellín-Carcelén
Rosario Gil
Robert C. Callaghan
José M. Martín
Vicent Alonso
Amelia Murgui
Lara Navarro
Silvia Calabuig
José Antonio López-Guerrero
Esperanza Jordá
Antonio Pellín
Publication date
01-08-2012
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 6/2012
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-012-9476-2

Other articles of this Issue 6/2012

Clinical & Experimental Metastasis 6/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine